4D Molecular Therapeutics, Inc.
FDMT
Positions held
Your positionsFDMT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $701.60M | Enterprise value | $379.48M | Trailing P/E | — | Forward P/E | -3.10 |
| PEG | — | Price / book | 1.72 | Beta | 2.74 | Dividend yield | 0.00% |
| Revenue growth | 251.1% | Earnings growth | — | Gross margin | -1.6% | Operating margin | -20.4% |
| Profit margin | -1.9% | ROE | -43.3% | ROA | -25.1% | Debt / equity | 0.10 |
| Current ratio | 8.03 | Free cash flow | -$90.77M | Analyst recommendation | strong_buy | Mean target | $28.09 |
| 52w high | $16.93 | 52w low | $6.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.8M | $3.0M | $85.1M | $0.1M | $0.0M | — |
| Op margin | -2037.2% | -2416.1% | 17.3% | -67983.3% | -396373.3% | — |
| Net income | -$72.9M | -$68.8M | $19.4M | -$56.9M | -$54.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$77.0M | -$73.6M | $14.7M | -$61.2M | -$59.5M | — |
- Revenue +24% vs prior quarter ($3.8M vs $3.0M).
- Operating margin expanded to -2037.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $85.2M | $0.0M | $20.7M | $3.1M |
| Op margin | -187.2% | -507678.4% | -544.6% | -3516.5% |
| Net income | -$140M | -$161M | -$101M | -$107M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$160M | -$188M | -$113M | -$110M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · 4D Molecular Therapeutics Insider Sold Shares Worth $753,937, According to a Recent SEC Filing
2026-10-05 · 4DMT to Host Investor Day on October 21, 2026
2026-09-29 · This is the top biotech stock pick from B Riley Securities
2026-09-28 · OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
2026-09-28 · 4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema
2026-09-28 · 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
2026-09-16 · 4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing
2026-09-14 · Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral
2026-09-11 · 4DMT Announces New Employment Inducement Grants
2026-08-25 · 4DMT to Participate in Upcoming Investor Conferences
2026-08-17 · OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
2026-08-14 · 4DMT Announces New Employment Inducement Grants
Price (daily)
Full chart · RSI · MACD · patterns